Low Risk of Hemolytic Uremic Syndrome after Early Effective Antimicrobial Therapy for Shigella dysenteriae Type 1 Infection in Bangladesh

摘要

Background. Hemolytic uremic syndrome (HUS) may complicate up to 15% of cases of Shiga toxin (Stx)—expressing enterohemorrhagic Escherichia coli (STEC) O157:H7 infections in children. Administration of antimicrobials has been reported to increase the risk of STEC-associated HUS by >10-fold, presumably by increasing the expression and release of Stx by dying STEC bacteria. Shigella dysenteriae type 1 also expresses Stx. However, the effect of antimicrobial therapy on Stx release and the risk of HUS in humans is unknown.